Class C Medical Device Import License in India

Common Mistakes Under MDR 2017 — Practically Explained

By Ankur K. Khare – Biomedical Engineer | Regulatory Affairs Specialist | Founder – RegIntel Med India

Importing a Class C medical device in India is not just an application.

It is a regulatory strategy decision.

Under the Medical Device Rules (MDR) 2017, Class C devices fall under moderate-to-high risk, meaning:

Your documentation depth increases
CDSCO scrutiny intensifies
Approval timelines expand
Query handling becomes critical

Most delays in Class C import license applications (MD-14 / MD-15) happen due to preventable strategic mistakes.

This article explains those mistakes practically — not just legally.

Why Class C Import Applications Face Higher Scrutiny

For Class C medical device import in India:

✔ Application is filed in Form MD-14
✔ License is granted in Form MD-15
✔ Device Master File (DMF) is mandatory
✔ Plant Master File (PMF) is required
✔ Indian Authorized Agent is compulsory
✔ Detailed technical documentation is expected

CDSCO does not treat Class C like Class A or B.

The review is document-driven and risk-focused.

1️⃣ Incorrect Classification Assumption

Many importers assume:

“If it is CE approved, approval in India will be easy.”

Wrong.

CDSCO evaluates classification based on:

Intended use
Mode of action
Risk to patient
Level of invasiveness
Impact on diagnosis or therapy

Misclassification creates:

Queries
Rejection
Re-filing delays

🔍 Regulatory Reality
Classification must align with claims in labeling and technical documentation.

2️⃣ Weak Device Master File (DMF)

The Device Master File for Class C import must be comprehensive.

Common DMF issues include:

Incomplete intended use
Poorly written risk management summary
Missing clinical performance justification
Inconsistent specifications
Lack of validation evidence

CDSCO often raises structured technical queries when DMF lacks clarity.

For Class C devices, DMF strength determines approval confidence.

3️⃣ Inadequate Plant Master File (PMF)

Many applicants rely solely on ISO 13485 certificate.

That is not sufficient.

PMF must clearly describe:

Manufacturing workflow
Quality control systems
Sterilization process (if applicable)
Process validation
Supplier controls

Incomplete PMF leads to extended review cycles.

4️⃣ Labeling Non-Compliance

For Class C medical device import in India, labeling must include:

Importer name & address
Manufacturing details
Regulatory declarations
Correct intended use
Batch/lot information

Even minor inconsistencies between:

Label
DMF
Free Sale Certificate

Can trigger objections.

⚠️ Common Mistake
Marketing language that increases perceived risk classification.

5️⃣ Free Sale Certificate (FSC) Mismatch

CDSCO cross-checks FSC carefully.

Mismatch areas include:

Device name variations
Intended use differences
Country of origin approval discrepancies

Even spelling inconsistencies can create regulatory friction.

For Class C, documentation precision matters.

6️⃣ Underestimating CDSCO Query Handling

Almost all Class C import license applications receive queries.

The real issue is not queries.

It is weak responses.

Poorly structured replies can:

Reset review timelines
Trigger further clarification rounds
Increase regulatory uncertainty

Query response strategy must be prepared before submission.

7️⃣ No Feasibility Assessment Before Filing

Many founders jump directly into MD-14 submission.

Without:

Risk gap analysis
Documentation readiness review
Timeline realism check
Authorized Agent clarity

This leads to:

Cost escalation
Repeated delays
Strategic confusion

A structured feasibility review can significantly reduce approval risk.

How to Approach Class C Import Strategically

Before filing MD-14:

✔ Lock intended use precisely
✔ Validate classification formally
✔ Review DMF structure internally
✔ Align labeling with documentation
✔ Verify Free Sale Certificate wording
✔ Prepare for technical queries

Regulatory success is preparation-driven.

Not form-driven.

A Simple Reality Check

Before submitting your Class C medical device import application, ask:

▢ Is our intended use language precise and controlled?
▢ Does our Device Master File withstand scrutiny?
▢ Are PMF and QMS documents aligned?
▢ Is labeling fully compliant with MDR 2017?
▢ Do we have a clear Authorized Indian Agent structure?

If any answer is uncertain — pause before filing.

Final Thought

Class C medical device import approval under MDR 2017 is absolutely achievable.

But it requires:

Documentation discipline
Regulatory clarity
Structured risk management
Strategic planning

Regulation is not paperwork.

It is risk governance.

Teams that approach Class C imports strategically:

Reduce approval delays
Avoid rework cycles
Build regulatory confidence
Accelerate market entry

Preparation determines approval.

About the Author

Ankur Khare is a Biomedical Engineer and Regulatory Affairs Specialist working in Indian medical device compliance. He focuses on MDR 2017 strategy, CDSCO licensing pathways, and regulatory intelligence for manufacturers and importers.

Search This Blog

MedReg Intel